iShares US Medical Devices

ResMed and Oura Partner to Enhance Sleep Health Education and Care Pathways for US Members

Resona Asset Management Reduces Stake in Intuitive Surgical by 13.1%

Boston Scientific Announces Positive Results from SEISMIQ™ 4CE FRACTURE IDE Trial

FAMAR Group Signs Contract Manufacturing Agreement with GE HealthCare to Expand Iodine Contrast Agent Capacity

Stryker Agrees to Acquire Amplitude Vascular Systems for $835 Million

Boston Scientific Average Stock Price Target Cut to $83.8, Market Maintains Buy Consensus

Edwards Lifesciences EVP Donald E. Bobo Jr. Sells $1.47M in Shares

Bank of America Lowers Intuitive Surgical Target Price to $520, Maintains Buy Rating

Boston Scientific Signs $2 Billion Accelerated Share Repurchase Agreement

Boston Scientific Invests $1.5 Billion for 34% Stake in MiRus with Option to Acquire Balloon-Expandable TAVR System for $3 Billion

GEHC Receives 'Hold' Consensus from 17 Brokers, Executives Buy Shares to Show Confidence

Wall Street Zen Upgrades Intuitive Surgical to Buy; Earnings and Revenue Beat Expectations

Macquarie and Citibank Reiterate Buy Rating on ResMed CHESS Depositary Interests

Stryker partners with Max Smart Hospital to advance surgical training for robotic-assisted joint replacements

NVision Completes $55 Million B Round Led by Abbott to Expand Quantum Computing Platform

Edward Lifesciences CEO Bernard J. Zallouk Sells Shares

Abbott Laboratories Sees Rising Dividend Yield Amid High Legal Costs and Infant Formula Litigation

GE HealthCare to Showcase AI-driven Radiotherapy Tools at ESTRO 2026

GE HealthCare Director Receives Restricted Stock Units and Buys Stocks

BD Medical applies for issuance of 600 million euros of notes

Amesite

InMed Pharmaceuticals

Meiwu Tech

Generation Income Properties

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

MetaVia

Phoenix Asia

Co-Diagnostics

NextNRG

BAYVIEW ACQUISITION CORPORATION COM USD0.0001 (S/R) 17/11/2028

Pinned News

置顶新闻

Boston Scientific Advances Coronary Calcium Treatment With Positive Trial Results

Boston Scientific announced positive results from the FRACTURE trial for its SEISMIQ 4CE coronary IVL catheter, achieving primary safety and effectiveness goals in severe CAD patients. The trial showed a 93.3% freedom from major adverse cardiac events and a 93.7% procedural success rate. The device aims to improve stent placement by fracturing calcium buildup in arteries. Boston Scientific shares rose 2.27% to $57.19 following the announcement.

benzinga_article

Boston Scientific

SPDR S&P Health Equip

S&P 500

Stellantis NV

ICCM

IceCure Medical reported a 89.4% recurrence-free rate at 4 years for its ProSense cryoablation system in kidney cancer trials. The ICESECRET trial results support its use in small renal tumors. Additionally, early-stage breast cancer data showed no residual cancer and high patient satisfaction, while fibroadenoma findings indicated significant lesion shrinkage, suggesting a promising minimally invasive approach.

PUBT

Icecure Medical

IceCure ProSense kidney cancer trial shows 89.4% recurrence-free rate at 4 years

AMIX

SBIO

LABU

A revolutionary technology has been developed that allows for minimally invasive transvascular access to nerve targets and tissues. This innovative method enables access through and beyond the lumen wall, providing a less invasive approach for procedures. This breakthrough is set to significantly improve treatment options for patients, with a success rate of over 90% in initial clinical trials. This technology is expected to benefit a wide range of medical fields and has the potential to transform minimally invasive procedures globally.

Unusual Whales

Autonomix Medical

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation

Nexalin has completed the acquisition of the PONM digital health platform from GreenLight Ventures for $1.3 million, paid in Nexalin stock. The deal includes an exclusive license for AI-enabled software features and supports a planned FDA trial for HALO Clarity. GreenLight will also become an equity holder and provide ongoing support.

Nexalin Tech

NEXALIN TECHNOLOGY INC C/WTS 22/09/25(TO PUR COM)

Nexalin closes acquisition of PONM digital health platform for USD 1.3 million

RNXT

RenovoRx (RNXT) reported a record Q1 2026 revenue of $563,000, a 136% increase from Q4 2025. The company has expanded its commercial cancer centers to 16 and aims for 36 by year-end. Management reiterated a 2026 revenue target of $3-4 million, supported by a strong pipeline and cash position of $12.4 million. The TIGER-PACT Phase III trial is nearing completion, with 93% of patient enrollment achieved. Operating expenses are expected to remain stable, facilitating further revenue growth.

Motley Fool

RenovoRx

iShares Global Healthcare

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

iShares US Pharma

VG Health

RenovoRx (RNXT) Q1 2026 Earnings Transcript

ISRG

ISUL

Resona Asset Management Co. Ltd. reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 13.1% in Q4, now holding 212,119 shares valued at $120.6 million. Other hedge funds, like Brighton Jones LLC and Main Street Financial Solutions LLC, increased their stakes. Insider sales included EVP Gary Loeb selling 400 shares and SVP Mark Brosius selling 2,362 shares. Intuitive Surgical's stock opened at $439.92, with a market cap of $155.8 billion and a recent earnings report showing a 23% revenue increase year-over-year.

Market Beat

Intuitive Surgical

GraniteShares 2x Long ISRG Daily ETF

Resona Holdings, Inc.

Truist Financial

Resona Asset Management Co. Ltd. Reduces Stock Holdings in Intuitive Surgical, Inc. $ISRG

Radnor Capital Management LLC increased its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 130.6% in Q4, now holding 6,000 shares valued at $1.65 million. Other institutional investors also raised their positions. West Pharmaceutical's stock opened at $304.31, with a market cap of $21.50 billion and a P/E ratio of 40.68. The company reported strong earnings, beating estimates, and announced a $1 billion stock repurchase plan.

West Pharmaceutical

Arcadian Asset

Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST

Stryker Corporation has acquired Amplitude Vascular Systems for up to $835 million to enhance its vascular treatment business. Amplitude developed a hydraulic intravascular lithotripsy platform for treating calcified peripheral arterial disease. The acquisition is seen as a strategic move to expand Stryker's offerings, including the Pulse System, which may provide improved treatment options. Stryker's stock is currently trading at $313.76, up 0.17%.

rttnews

Stryker

Stryker Buys Amplitude Vascular Systems For Upto $835 Mln To Expand Vascular Treatment Business

Resona Asset Management Co. Ltd. reduced its stake in Danaher Corporation (NYSE:DHR) by 12.7% in Q4, now holding 448,050 shares valued at approximately $102.77 million. Other institutional investors have also adjusted their positions. Analysts have lowered price targets for Danaher, with a consensus rating of 'Moderate Buy' and a price target of $238.65. Danaher reported a quarterly EPS of $2.06, exceeding estimates, and announced a quarterly dividend of $0.40.

Danaher

Goldman Sachs

Wells Fargo

Johnson Controls

GS Hldg R

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Resona Asset Management Co. Ltd. Cuts Position in Danaher Corporation $DHR

Autonomix Medical has been granted U.S. Patent No. 12,544,131 for its transvascular monitoring and treatment systems that validate nerve-targeted procedures in real time using electrophysiological signals. The patent includes catheter-based tools with deployable probes for accessing tissue beyond vessel walls and features multi-site sensing and closed-loop control for therapy adjustments.

Autonomix Medical wins US patent for transvascular monitoring, real-time procedural validation system

FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints | BSX Stock News

StockTitan